28 results on '"Sutherby, Rosanna"'
Search Results
2. Expect to see more GLP-1s: Drug developers hope to get in on the action in the hot-selling drug class
3. ADCs are a hot ticket: Major drug companies have been snatching up biotech companies that are developing antibody-drug conjugates (ADCs) targeting a variety of cancers
4. Dermatology's embrace of JAK inhibitors: The FDA has approved six with dermatologic indications and more are in late-stage trials
5. Psychedelics: Once outcasts, now in trials: Biotech companies and researchers are investigating whether psychedelics could be used to treat a variety of mental health problems, including post-traumatic stress disorder and depression
6. Two more TROP2-seeking ADCs in late-stage development: If approved, they would join Trodelvy as a treatment for triple-negative breast cancer
7. mRNA vaccine momentum: The success of mRNA against COVID-19 has led to a surge of mRNA vaccines being developed for other diseases
8. MEET A NEW NSCLC TARGET: c-MET: Two drugs that target the c-MET protein are in phase 3 trials
9. New COVID-19 vaccines are in late-stage trials: For now, only the Pfizer and Moderna vaccines have full FDA approval, but many candidates are in phase 2 or 3 trials
10. Adding SERDs to the adjuvant armamentarium: Selective estrogen receptor degraders are vying to join aromatase inhibitors and selective estrogen receptor modulators as therapy after the initial treatment of breast cancer
11. New treatments to lower lipoprotein(a): Lipoprotein(a) is a cardiovascular disease risk factor that does not change with diet and exercise. There are no FDA-approved treatments, but two candidates are in phase 3 trials
12. Gene replacement therapy for DMD: The race is on: Sarepta Therapeutics and Roche are competing with Pfizer to develop the first gene replacement therapy for Duchenne muscular dystrophy. Sarepta and Roche are ahead after the FDA put a clinical hold on Pfizer's product
13. RSV vaccine development is on the comeback trail: Research stalled for decades after deaths in a 1960s trial. Now Pfizer and other companies are reporting results for a vaccine against respiratory syncytial virus infections
14. Hemostatic rebalancing agents in hemophilia care: Expensive gene therapy has grabbed the headlines, but three promising drugs that work in the coagulation pathway are in late-stage development
15. Researchers pinpoint reason for waning COVID-19 vaccine protection in patients with IBD treated with TNF-alpha blockers
16. MS post-menopause: Relapse rate down, disability up
17. Some momentum for Alzheimer's drugs: Although Aduhelm stumbled, Leqembi has received full FDA approval, and Eli Lilly has reported positive results for donanemab
18. For ulcerative colitis, two first-in-class candidates and an interleukin-23 competition: A Swedish and a French company have treatments with novel mechanisms of action in late-stage development. Meanwhile, AbbVie, Janssen and Eli Lilly are vying to get the first interleukin-23 inhibitor for ulcerative colitis on the market
19. For ALS treatments, three genes are targets: Dozens of gene mutations associated with amyotrophic lateral sclerosis have been identified. Drug developers have homed in on a trio of genes
20. The NASH cupboard, now bare, has two candidates: Ocaliva and resmetirom may be approved by the FDA this year
21. Drugs on the fast track as treatments for PTSD: Several drugs with novel mechanisms of action have been put on the pathway for speedier approval decisions by the FDA. Phase 2 and 3 trials are underway
22. Gene therapies for hemophilia. Possibly curative, likely ultraexpensive: Three gene therapies in late-stage development are designed to supply working copies of genes that people with hemophilia are missing. They may be one-time, curative treatments, but the seven-figure price tags will be an issue
23. A surge of biologics for severe asthma: Six are on the market and more are in the pipeline. Biologics target the inflammatory cytokines involved in the pathogenesis of asthma
24. Antibody-drug conjugates find and kill cancer cells: Three ADCs are in late-stage trials as treatments for patients with non-small cell lung cancer
25. For atopic dermatitis treatment, an abundance of options Across the globe, new drugs--injections, topical and oral--are being developed to help patients with eczema
26. Multiple sclerosis Some drugs new, some tried-and-true: The race is on to be the fi rst-approved Bruton tyrosine kinase inhibitor. Meanwhile, trials are underway to test statins and metformin as treatments for multiple sclerosis
27. Removing the CD47 'do not eat me' sign: Gilead's magrolimab is the leading CD47 immune checkpoint inhibitor in development
28. For plaque psoriasis treatment, abundance gets more company: Nonsteroidal topical agents and TYK2 inhibitors may join an already full armamentarium
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.